Alembic Pharma Share Price in Focus After Getting Tentative Approval From USFDA for Cancer Drug Larotrectinib

Alembic Pharmaceuticals Ltd. has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules in 25 mg and 100 mg strengths. The development is expected to keep Alembic Pharma share price on investors' radar as the company expands its portfolio in the highly regulated US generics market.

The approved product is the generic equivalent of Vitrakvi, marketed by Bayer Healthcare Pharmaceuticals. Larotrectinib is a kinase inhibitor used to treat adult and pediatric patients with certain types of solid tumors associated with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.

Potential 180-Day Market Exclusivity Opportunity

A key highlight of the approval is Alembic's position as the sole first applicant to file the ANDA with a Paragraph IV certification under the Hatch-Waxman Act, according to the latest FDA database.

Upon receiving final approval from the USFDA, the company may become eligible for 180 days of generic marketing exclusivity in the United States. Such exclusivity periods are closely watched by investors as they can provide a significant revenue opportunity before additional generic competitors enter the market.

The development could serve as a positive trigger for Alembic Pharma share price, particularly given the profitability associated with limited-competition generic launches.

$91 Million Market Opportunity in the US

According to IQVIA data, Larotrectinib Capsules recorded an estimated market size of $91 million in the United States for the 12 months ended March 2026.

The approval further strengthens Alembic's US generics business. The company now has a cumulative total of 241 ANDA approvals from the USFDA, comprising 221 final approvals and 20 tentative approvals.

Alembic continues to focus on expanding its regulated market presence through a combination of complex generic launches, research-driven product development and manufacturing capabilities.

Read more: Bharti Airtel Deploys Over 2,900 5G New Sites Across 4 States, Rebrands Priority Postpaid Offering as Fast Lane.

Conclusion

The USFDA tentative approval for Larotrectinib Capsules marks another important milestone for Alembic Pharmaceuticals in the US market. While investors will await final approval and clarity on the exclusivity timeline, the potential access to a $91 million market and the possibility of 180-day generic exclusivity make this development significant. As a result, Alembic Pharma share price is likely to remain in focus among market participants in the coming sessions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.